Cited by 342Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Open access

Zonder, Jeffrey A., Mohrbacher, Ann F., Singhal, Seema, van Rhee, Frits, Bensinger, William I., Ding, Han, Fry, John, Afar, Daniel E. H., Singhal, Anil K.·2012·Blood

DOI 10.1182/blood-2011-06-360552PMC PMC4467882

Open this paper in CoChat — free account Open PDF

Abstract

This multicenter, first-in-human study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of the anti-CS1 monoclonal antibody elotuzumab. A standard 3 + 3 design was used to determine maximum tolerated dose; dose-limiting toxicities were assessed during cycle 1. Thirty-five patients with relapsed/refractory multiple myeloma were treated with intravenous elotuzumab at doses ranging from 0.5 to 20 mg/kg every 2 weeks. Patients who achieved at least stable disease after 4 treatments could receive another 4 treatments. No maximum tolerated dose was identified up to the maximum planned dose of 20 mg/kg. The most common adverse events, regardless of attribution, were cough, headache, back pain, fever, and chills. Adverse events were generally mild to moderate in severity, and adverse events attributed to study medication were primarily infusion-related. Plasma elotuzumab levels and terminal half-life increased with dose whereas clearance decreased, suggesting target-mediated clearance. CS1 on bone marrow–derived plasma cells was reliably saturated (≥ 95%) at the 10-mg/kg and 20-mg/kg dose levels. Using the European Group for Bone and Marrow Transplantation myeloma response criteria, 9 patients (26.5%) had stable disease. In summary, elotuzumab was generally well tolerated in this population, justifying further exploration of this agent in combination regimens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2011-06-360552

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Tai, Y., Catley, L. P., Mitsiades, C. S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3630 · Cited by 130
Retracted
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
High Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
Brocken, P., van der Heijden, E. H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus‐Oei, L. (2013) · Respiration · doi:10.1159/000347096 · Cited by 4,011
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309

Show all 42 references

Sorted by citations

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Multiple myeloma
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 935
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citation
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease
Mattoo, H., Mahajan, V. S., Maehara, T., Deshpande, V., Della‐Torre, E., Wallace, Z. S., Kulikova, M., Drijvers, J. M., Daccache, J., Carruthers, M. N., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1330 · Cited by 411
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S. I., & June, C. H. (2014) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 325
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Collins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Drug resistance in multiple myeloma
Robak, P. J., Dróźdż, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 291
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
Flores-Montero, J. A., Tute, R. M. D., Paiva, B., Pérez, J. J., Böttcher, S., Wind, H., Sanoja-Flores, L., Puig, N., Lécrevisse, Q., Vídriales, M., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21265 · Cited by 263
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Trudel, S., Lendvai, N. K., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 255
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Gogishvili, T., Danhof, S., Prommersberger, S., Rydzek, J., Schreder, M., Brede, C., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-04-778423 · Cited by 246
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Ocio, E. M., Richardson, P. G. G., Rajkumar, S. V., Palumbo, A. P., Mateos, M., Orlowski, R. Z., Kumar, S. K., Usmani, S. Z., Roodman, D., Niesvizky, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 239
Chimeric antigen receptor T cell therapy: 25years in the making
Gill, S. I., Maus, M. V., & Porter, D. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.10.003 · Cited by 245
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Casneuf, T., Xu, X. S., Adams, H., Axel, A. E., Chiu, C. W., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006866 · Cited by 231
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Zah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
Retracted
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Engelhardt, M. M., Terpos, E., Kleber, M., Gay, F., Wäsch, R., Morgan, G. J., Cavo, M., van de Donk, N. W. C. J., Beilhack, A., Bruno, B., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099358 · Cited by 217
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balasa, B., Yun, R., Belmar, N. A., Fox, M., Chao, D. T., Robbins, M. D. H., Starling, G. C., & Rice, A. G. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1610-3 · Cited by 156
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
Richardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00197-0 · Cited by 156
Self-citation
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 141
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
Dosani, T., Carlsten, M., Maric, I., & Landgren, O. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.32 · Cited by 135
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Campbell, K. S., Cohen, A. D., & Pazina, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02551 · Cited by 125
Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐ CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma
Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan-Khan, A. A., Siegel, D. S. D., Horne, H. B., Wegener, W. A., & Goldenberg, D. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12565 · Cited by 126
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02815 · Cited by 114
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
Veillette, A., & Guo, H. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.04.003 · Cited by 116
Robust isolation of malignant plasma cells in multiple myeloma
Frigyesi, I., Adolfsson, J., Ali, M., Christophersen, M. K., Johnsson, E., Turesson, I., Gullberg, U., Hansson, M., & Nilsson, B. (2014) · Blood · doi:10.1182/blood-2013-09-529800 · Cited by 116
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 112
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 113
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109
A phase 1 study of lucatumumab, a fully human anti‐ CD 40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
Bensinger, W., Maziarz, R. T., Jagannath, S., Spencer, A. G., Durrant, S., Becker, P. S., Ewald, B., Bilic, S., Rediske, J. J., Baeck, J., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09251.x · Cited by 108
Self-citation
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
Drgoňa, Ľ., Gudiol, C., Lanini, S., Salzberger, B., Ippolito, G., & Mikulska, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.022 · Cited by 107
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Malaer, J. D., & Mathew, P. A. (2017) · PubMed Central · Cited by 100
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
Amatya, C., Pegues, M. A., Lam, N., Vanasse, D., Geldres, C., Choi, S. H., Hewitt, S. M., Feldman, S. A., & Kochenderfer, J. N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.008 · Cited by 106
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
Lonial, S., Durie, B. G. M., Palumbo, A. P., & Miguel, J. F. S. (2015) · Leukemia · doi:10.1038/leu.2015.223 · Cited by 95
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
Rasche, L., Duell, J., Castro, I. C., Dubljevic, V., Chatterjee, M., Knop, S. T., Hensel, F., Rosenwald, A., Einsele, H., Topp, M. S., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117945 · Cited by 93
Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
Guo, H., Cruz‐Munoz, M., Wu, N., Robbins, M. D. H., & Veillette, A. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01107-14 · Cited by 88
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
Pazina, T., James, A. M., Macfarlane, A. W., Bezman, N., Henning, K. A., Bee, C., Graziano, R. F., Robbins, M. D. H., Cohen, A. D., & Campbell, K. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339853 · Cited by 88
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
James, A. M., Cohen, A. D., & Campbell, K. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00481 · Cited by 83
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
How I treat fragile myeloma patients
Larocca, A., & Palumbo, A. P. (2015) · Blood · doi:10.1182/blood-2015-05-612960 · Cited by 76
Actors on the Scene: Immune Cells in the Myeloma Niche
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., Re, V. D., Argentiero, A., Silvestris, N., Vacca, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599098 · Cited by 73
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
Murata, K., McCash, S. I., Carroll, B. L., Lesokhin, A. M., Hassoun, H., Lendvai, N. K., Korde, N., Mailankody, S., Landau, H. J., Koehne, G., et al. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.09.015 · Cited by 71
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
Berdeja, J. G., Jagannath, S., Zonder, J. A., Badros, A. Z., Kaufman, J. L., Manges, R., Gupta, M., Tendolkar, A. V., Lynch, M. J., Bleickardt, E. W., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.007 · Cited by 70
Self-citation
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 68
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Magen, H., & Muchtar, E. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716652862 · Cited by 69
Immune Therapies in Multiple Myeloma
Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Kikuchi, J., Hori, M., Iha, H., Toyama‐Sorimachi, N., Hagiwara, S., Kuroda, Y., Koyama, D., Izumi, T., Yasui, H., Suzuki, A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0525-6 · Cited by 67
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Yang, W., & Lin, S.-F. (2015) · BioMed Research International · doi:10.1155/2015/341430 · Cited by 69
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma
Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J. L., Gharibo, M. M., Sher, T., Bojanini, L., Kirby, M. W., & Chanan-Khan, A. A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.018 · Cited by 65
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
Kazandjian, D. G., & Landgren, O. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.008 · Cited by 63
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 65
Immune-based therapies in the management of multiple myeloma
Zanwar, S., Nandakumar, B. N., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00350-x · Cited by 64
Elotuzumab for the treatment of multiple myeloma
Wang, Y., Sanchez, L. J., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0284-z · Cited by 65
The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
Hoyos, V., & Borrello, I. (2016) · Blood · doi:10.1182/blood-2016-05-636357 · Cited by 62
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., Nickho, H., Akbarpour, M., & Delbandi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174138 · Cited by 59
Monoclonal antibody therapy in multiple myeloma
Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61
Chimeric Antigen Receptor ( CAR ) therapy for multiple myeloma
Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N., & Luetkens, T. (2016) · British Journal of Haematology · doi:10.1111/bjh.13889 · Cited by 60
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 61
Immunopathogenesis and immunotherapy of multiple myeloma
Tamura, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2405-7 · Cited by 59
Current developments in immunotherapy in the treatment of multiple myeloma
Köhler, M., Greil, C., Hudecek, M., Lonial, S., Raje, N. S., Wäsch, R., & Engelhardt, M. M. (2018) · Cancer · doi:10.1002/cncr.31243 · Cited by 58
Daratumumab granted breakthrough drug status
Laubach, J. P., Tai, Y., Richardson, P. G. G., & Anderson, K. C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.889681 · Cited by 57
A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
Rasche, L., Ménoret, E., Dubljevic, V., Menu, E., Vanderkerken, K., Lapa, C., Steinbrunn, T., Chatterjee, M., Knop, S. T., Düll, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3111 · Cited by 57
Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences
McCudden, C. R., Jacobs, J. F. M., Keren, D. F., Caillon, H., Dejoie, T., & Andersen, K. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.08.013 · Cited by 57
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 56
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56
Interventions for cough in cancer
Molassiotis, A., Bailey, C., Caress, A., & Tan, J.-Y. B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007881.pub3 · Cited by 55
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Nijhof, I. S., Franssen, L. E., Levin, M., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 55
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Harding, T., Baughn, L. B., Kumar, S. K., & Ness, B. V. (2019) · Leukemia · doi:10.1038/s41375-018-0362-z · Cited by 56
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Monoclonal antibodies — A new era in the treatment of multiple myeloma
Jelı́nek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 50
Current use of monoclonal antibodies in the treatment of multiple myeloma
Varga, C., Maglio, M. E., Ghobrial, I. M., & Richardson, P. G. G. (2018) · British Journal of Haematology · doi:10.1111/bjh.15121 · Cited by 51
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Pazina, T., James, A. M., Colby, K. B., Yang, Y., Gale, A., Jhatakia, A., Kearney, A. Y., Graziano, R. F., Bezman, N., Robbins, M. D. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0579 · Cited by 50
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
Allegra, A., Penna, G., Alonci, A., Russo, S., Greve, B., Innao, V., Minardi, V., & Musolino, C. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12107 · Cited by 50
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Hansson, M., Gimsing, P., Badros, A. Z., Niskanen, T. M., Nahi, H., Offner, F. C., Salomo, M., Sonesson, E., Mau‐Sørensen, M., Stenberg, Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3090 · Cited by 49
Treatment of relapsed and refractory multiple myeloma
Lee, J. H., & Kim, S. (2020) · Blood Research · doi:10.5045/br.2020.s008 · Cited by 50
Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma
Mateos, M., Granell, M., Oriol, A., Martínez‐López, J., Bladé, J., Hernández, M., Martín, J., Gironella, M., Lynch, M. J., Bleickardt, E. W., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14263 · Cited by 47
Self-citation
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma
Griffin, P. T., Ho, V. Q., Fulp, W. J., Nishihori, T., Shain, K. H., Alsina, M., & Baz, R. (2015) · Cancer · doi:10.1002/cncr.29533 · Cited by 48
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Neri, P. E., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 49
New Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 49
Emerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
Bonello, F., Mina, R., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers12010015 · Cited by 45
How I treat the young patient with multiple myeloma
Gandolfi, S., Prada, C. P., & Richardson, P. G. G. (2018) · Blood · doi:10.1182/blood-2017-05-693606 · Cited by 47
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Radocha, J., van de Donk, N. W. C. J., & Weisel, K. C. (2021) · Cancers · doi:10.3390/cancers13071571 · Cited by 45
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 48
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma
Zhang, T., Wang, S., Lin, T.-F., Xie, J., Zhao, L., Liang, Z., Li, Y., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16987 · Cited by 42
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab
Nooka, A. K., Gleason, C. L., Sargeant, M. O., Walker, M., Watson, M., Panjic, E. H., & Lonial, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00143 · Cited by 42
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Shah, N. D., Aiello, J., Avigan, D., Berdeja, J. G., Borrello, I., Chari, A., Cohen, A. D., Ganapathi, K. A., Gray, L., Green, D. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000734 · Cited by 47
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
Nishida, H., Hayashi, M., Morimoto, C., Sakamoto, M., & Yamada, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0127-y · Cited by 41
Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
Orlowski, R. Z. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.007 · Cited by 39
The development of potential antibody-based therapies for myeloma
Sherbenou, D. W., Behrens, C. R., Yang, S., Wolf, J. L., Martin, T. G., & Liu, B. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.09.011 · Cited by 39

Authors: Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K.
Affiliations: Wayne State University (US)
University of Southern California (US)
Northwestern University (US)
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;
Fred Hutch Cancer Center (US)
AbbVie Biotherapeutics (United States) (US)
ORCID: Zonder, Jeffrey A.
Mohrbacher, Ann F.
Singhal, Seema
Ding, Han
Fry, John
Venue: Blood
Publisher: American Society of Hematology
Published: 2012-07-19
Volume: 120
Issue: 3
Pages: 552-559
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2011-06-360552
PMC: PMC4467882
OpenAlex: W2000130439
Cited by: 342
References: 42
Citations by year: 2026: 3 · 2025: 2 · 2024: 8 · 2023: 10 · 2022: 16 · 2021: 22 · 2020: 34 · 2019: 25 · 2018: 42 · 2017: 41 · 2016: 48 · 2015: 38 · 2014: 28 · 2013: 21 · 2012: 4
FWCI: 11.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
National Cancer Institute (P01CA055819)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: elotuzumab, multiple myeloma, CS1, syndecan-1, monoclonal antibodies, dose escalation, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, safety and tolerability, relapsed/refractory multiple myeloma, stable disease
MeSH terms: Aged, Aged, 80 and over, Antineoplastic Agents, Bone Marrow, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Severity of Illness Index, Treatment Outcome, Lymphocyte Count, Chemokine CXCL10, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks